المؤلفون: Elizabeth Lenihan, Michael O'Dwyer, I. Parker, Aideen E. Ryan, A. Hernando, Philip Murphy, G. Hirakata, G. Gannon, Kevin Lynch, Serika D. Naicker, J. Walsh, Janusz Krawczyk, Alessandro Natoni, Robert Henderson, Vitaliy Mykytiv, Tara Kenny, Mary R. Cahill, Cian McEllistrim, E. Kinsella, John Quinn

المصدر: Blood Advances. 3:1815-1825

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Neutropenia, Antineoplastic Agents, Hormonal, CyBorD-DARA, Cyclophosphamide, Clinical Trials and Observations, Injections, Subcutaneous, Infections, Transplantation, Autologous, Gastroenterology, Dexamethasone, Bortezomib, Autologous stem-cell transplantation, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Multiple myeloma (MM), Antineoplastic Agents, Alkylating, Aged, Very Good Partial Response, Daratumumab (DARA), Intention-to-treat analysis, business.industry, Incidence, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, Autologous stem cell transplantation (ASCT), Hematology, Middle Aged, medicine.disease, Minimal residual disease, Transplantation, Treatment Outcome, Female, Multiple Myeloma, business, Ireland, Proteasome Inhibitors, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfcbd78010bcb124bff9b0f4f783711b
https://doi.org/10.1182/bloodadvances.2019000010